METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat esophageal cancer?
Disease control OngoingThis study tested if adding a new drug called cixutumumab to standard chemotherapy (paclitaxel) works better for people with advanced esophageal cancer that has spread. It involved 94 patients whose cancer had worsened after one prior treatment. The goal was to see if the combina…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Direct-Abdominal chemo tested for tough stomach cancers
Disease control OngoingThis early-stage study is testing whether delivering a chemotherapy drug called paclitaxel directly into the abdominal cavity is safe and tolerable for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find t…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug duo tested in fight against tough stomach cancers
Disease control OngoingThis early-stage study is testing the safety of combining two drugs, abemaciclib and ramucirumab, for people with advanced stomach or esophageal cancer that has spread and stopped responding to initial chemotherapy. The main goal is to see how safe the combination is and what sid…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control OngoingThis study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC